Clinical Trial Update: S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial S9922 evaluating combination chemotherapy with filgrastim, with or without thalidomide, for refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Neupogen (Filgrastim)
• Thalomid (thalidomide)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Multiple Myeloma | Phase 3 | Status: TERMINATED